Preclinical Assets Market, by Service ( Bioanalysis and DMPK studies (In vitro, In-vivo), Toxicology Testing (GLP, Non-GLP), compound management (Process R&D, Custom Synthesis, Asymmetric Synthesis & Others (Scale-up, cGMP, etc.), Safety Pharmacology, Ot
Description
Preclinical Assets Market, by Service ( Bioanalysis and DMPK studies (In vitro, In-vivo), Toxicology Testing (GLP, Non-GLP), compound management (Process R&D, Custom Synthesis, Asymmetric Synthesis & Others (Scale-up, cGMP, etc.), Safety Pharmacology, Others(Chemistry, etc.)), by Model type (Patient Derived Organoid (PDO) Model, Patient derived xenograft model), by End user (Biopharmaceutical Companies, Government Institutes & Others (Academic and Research institutes) ), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
Preclinical assets consist of various types of services such as Bioanalysis and DMPK (Drug Metabolism and pharmacokinetics) studies, which are further sub segmented into in vitro and in vivo analysis, toxicology testing, which are based on GLP and non GLP (Good Laboratory Practices), compound management process R&D (Research and development), custom synthesis, asymmetric synthesis, and others (Scale-up, cGMP (current good manufacturing practices), safety pharmacology. Preclinical assets have two types of models, patient derived organoid (PDO) model and patient derived xenograft model.
Market Dynamics
Increasing number of service launch in preclinical testing by the key market players is expected to drive growth of the global preclinical assets market during the forecast period. For instance, in July 2020, Skinobs, a cosmetic company, announced the launch of a new preclinical testing platform skinobs, an independent tool which provides a 360-degree vision of in vivo efficacy testing. This platform enables users to identify and select the testing methods depending on various criteria such as
Key features of the study:
In-vivo
Non-GLP
Custom Synthesis
Asymmetric Synthesis
Others (Scale-up, cGMP, etc.)
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
Preclinical assets consist of various types of services such as Bioanalysis and DMPK (Drug Metabolism and pharmacokinetics) studies, which are further sub segmented into in vitro and in vivo analysis, toxicology testing, which are based on GLP and non GLP (Good Laboratory Practices), compound management process R&D (Research and development), custom synthesis, asymmetric synthesis, and others (Scale-up, cGMP (current good manufacturing practices), safety pharmacology. Preclinical assets have two types of models, patient derived organoid (PDO) model and patient derived xenograft model.
Market Dynamics
Increasing number of service launch in preclinical testing by the key market players is expected to drive growth of the global preclinical assets market during the forecast period. For instance, in July 2020, Skinobs, a cosmetic company, announced the launch of a new preclinical testing platform skinobs, an independent tool which provides a 360-degree vision of in vivo efficacy testing. This platform enables users to identify and select the testing methods depending on various criteria such as
- Test Category: which include analytical tests, content-contenair interaction, ecotoxicity and biodegradability tests, safety tests, UV (Ultra Violet ) tests, etc.
- Claim: which include anti-ageing, anti-pollution, etc.
- Test support: which include cell cultures, 3D skin models, etc.
Key features of the study:
- This report provides an in-depth analysis of the global preclinical assets market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2022 – 2030, considering 2021 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global preclinical assets market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Eurofins Scientific, ICON plc, WuXi AppTec, Viroclinics Xplore, Medpace, Inc., Charles River Laboratories., Pharmatest Services, PPD Inc., SGS SA (SGS), Intertek Group plc, Labcorp Drug Development, Laboratory Corporation of America, Inc., Crown Bioscience, Comparative Biosciences, Inc., TCG Lifesciences Private Limited., Shanghai Medicilon Inc., Domainex, Absorption Systems, AmplifyBio, and IQVIA
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global preclinical assets market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global preclinical assets market
- Global Preclinical Assets Market, By Service:
- Bioanalysis and DMPK studies
In-vivo
- Toxicology Testing
Non-GLP
- Compound Management
Custom Synthesis
Asymmetric Synthesis
Others (Scale-up, cGMP, etc.)
- Safety Pharmacology
- Others (Chemistry, etc.)
- Global Preclinical Assets Market, By Model Type:
- Patient Derived Organoid (PDO) Model
- Patient derived xenograft model
- Global Preclinical Assets Market, By End User:
- Biopharmaceutical Companies
- Government Institutes
- Others (Academic and Research institutes)
- Global Preclinical Assets Market, By Region:
- North America
- US
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Eurofins Scientific*
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- ICON plc
- WuXi AppTec
- Viroclinics Xplore
- Medpace, Inc.
- Charles River Laboratories.
- Pharmatest Services
- PPD Inc.
- SGS SA (SGS)
- Intertek Group plc
- Labcorp Drug Development
- Laboratory Corporation of America, Inc.
- Crown Bioscience
- Comparative Biosciences, Inc.
- TCG Lifesciences Private Limited.
- Shanghai Medicilon Inc.
- Domainex
- Absorption Systems
- AmplifyBio
- IQVIA
Table of Contents
176 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Service
- Market Snapshot, By Model Type
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Technological Advancements
- Regulatory Landscape
- PEST Analysis
- 4. Global Preclinical Assets Market- Impact of Coronavirus (Covid-19) Pandemic
- Overall Impact
- COVID-19 Impact on the market
- 5. Global Preclinical Assets Market, By Service, 2017 – 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017– 2030
- Segment Trends
- Bioanalysis and DMPK studies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- In vitro
- In-vivo
- Toxicology Testing
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- GLP
- Non-GLP
- Compound Management
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Process R&D
- Custom Synthesis
- Asymmetric Synthesis
- Others (Scale-up and cGMP)
- Safety Pharmacology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Others (Chemistry, etc.)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- 6. Global Preclinical Assets Market, By Model Type, 2017 – 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Patient Derived Organoid (PDO) Model
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Patient derived xenograft model
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- 7. Global Preclinical Assets Market, By End User, 2017 – 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Biopharmaceutical Companies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Government Institutes
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Others (Academic and Research institutes)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- 8. Global Preclinical Assets Market, By Region, 2017 – 2030, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- UK
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 – 2030, (US$ Million)
- North Africa
- Central Africa
- South Africa
- 9. Competitive Landscape
- Heat Map Analysis
- Company Profile
- Eurofins Scientific
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- ICON plc
- WuXi AppTec
- Viroclinics Xplore
- Medpace, Inc.
- Charles River Laboratories.
- Pharmatest Services
- PPD Inc.
- SGS SA (SGS)
- Intertek Group plc
- Labcorp Drug Development
- Laboratory Corporation of America, Inc.
- Crown Bioscience
- Comparative Biosciences, Inc.
- TCG Lifesciences Private Limited.
- Shanghai Medicilon Inc.
- Domainex
- Absorption Systems
- AmplifyBio
- IQVIA
- Analyst Views
- 10. Section
- References
- Research Methodology
- About Us
- *Browse 36 market data tables and 25 figures on “Global Preclinical Assets Market” - forecast to 2030
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
